ProShare Advisors’s Avidity Biosciences RNAM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-32,086
| Closed | -$2.31M | – | 2000 |
|
|
2025
Q4 | $2.31M | Buy |
32,086
+10,066
| +46% | +$650K | ﹤0.01% | 684 |
|
|
2025
Q3 | $959K | Sell |
22,020
-5,948
| -21% | -$240K | ﹤0.01% | 826 |
|
|
2025
Q2 | $794K | Sell |
27,968
-2,046
| -7% | -$61K | ﹤0.01% | 899 |
|
|
2025
Q1 | $886K | Sell |
30,014
-6,895
| -19% | -$215K | ﹤0.01% | 850 |
|
|
2024
Q4 | $1.07M | Buy |
36,909
+9,573
| +35% | +$400K | ﹤0.01% | 879 |
|
|
2024
Q3 | $1.26M | Buy |
27,336
+10,180
| +59% | +$442K | ﹤0.01% | 751 |
|
|
2024
Q2 | $701K | Sell |
17,156
-1,722
| -9% | -$49.4K | ﹤0.01% | 833 |
|
|
2024
Q1 | $482K | Buy |
18,878
+1,898
| +11% | +$29.7K | ﹤0.01% | 1105 |
|
|
2023
Q4 | $154K | Buy |
16,980
+2,954
| +21% | +$19.7K | ﹤0.01% | 1703 |
|
|
2023
Q3 | $89.5K | Buy |
14,026
+249
| +2% | +$2.15K | ﹤0.01% | 1652 |
|
|
2023
Q2 | $153K | Buy |
13,777
+1,184
| +9% | +$14.9K | ﹤0.01% | 1604 |
|
|
2023
Q1 | $193K | Buy |
12,593
+1,203
| +11% | +$26.5K | ﹤0.01% | 1465 |
|
|
2022
Q4 | $253K | Buy |
11,390
+1,358
| +14% | +$20.2K | ﹤0.01% | 1334 |
|
|
2022
Q3 | $164K | Buy |
+10,032
| New | +$192K | ﹤0.01% | 1452 |
|
|
2022
Q2 | – | Sell |
-11,914
| Closed | -$221K | – | 2064 |
|
|
2022
Q1 | $221K | Sell |
11,914
-2,920
| -20% | -$49.6K | ﹤0.01% | 1824 |
|
|
2021
Q4 | $353K | Buy |
14,834
+252
| +2% | +$6.02K | ﹤0.01% | 1687 |
|
|
2021
Q3 | $359K | Sell |
14,582
-29
| -0.2% | -$630 | ﹤0.01% | 1415 |
|
|
2021
Q2 | $361K | Buy |
14,611
+1,301
| +10% | +$30.3K | ﹤0.01% | 1768 |
|
|
2021
Q1 | $290K | Buy |
13,310
+3,810
| +40% | +$93.3K | ﹤0.01% | 1826 |
|
|
2020
Q4 | $242K | Buy |
+9,500
| New | +$277K | ﹤0.01% | 1749 |
|
Other funds holding RNAM
ProShare Advisors's RNAM Position: Q1 2026 in Review
ProShare Advisors sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 32,086 shares — an estimated $2.31M sold.
ProShare Advisors first reported a position in RNAM in Q4 2020 and held it in 20 quarters. The position peaked at $2.31M in Q4 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.
- ProShare Advisors reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
- ProShare Advisors sold 32,086 Avidity Biosciences shares in Q1 2026, an estimated $2.31M.
- ProShare Advisors first reported a position in Avidity Biosciences in Q4 2020 and held it in 20 quarters.
- ProShare Advisors's Avidity Biosciences position peaked at $2.31M in Q4 2025.
- 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.
Based on ProShare Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.